American stocks have crashed this year, and are continuing to lag behind their global peers in countries like Germany, France ...

A European regulatory committee has rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The European stock markets were tracking lower in Friday trading as The Stoxx Europe 600 fell 0.69%, Germany's DAX was down 0.79%, the FTSE 100 in London was unchanged, France's CAC 40 declined 0.78%, ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...

The survey predicted the increase would happen within the next six months. Other industry news is on health care access in rural areas; Pfizer's alleged attempt to avoid taxes; and more.

Billionaire Dalio, head of the world's largest hedge fund, is considered a global authority on investing in China. The bank ...

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as ...